Compare Southwest Airlines Co (LUV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs State Street SPDR S&P Biotech ETF — how do they compare? Southwest Airlines Co trades at $40.99 (market cap $20.23B), while State Street SPDR S&P Biotech ETF trades at $149.89 (market cap $10.11B). The key difference: Southwest Airlines Co is far larger — about 2× State Street SPDR S&P Biotech ETF's market cap, and Southwest Airlines Co pays a 1.74% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| LUV | XBI | |
|---|---|---|
Market Cap | $20.23B | $10.11B |
Volume | 14,560,422 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $54.80 | $169.55 |
52-Week Low | $29.67 | $104.99 |
Typical Hold Time | 65 Days | 37 Days |
Enterprise Value | $23.33B | — |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.72, down 1.72% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates improving fundamentals with Q2 2026 EPS beating expectations at $0.94 versus $0.51 expected, while revenue growth continues from $28.06B in 2025 to projected $30.1B in 2026. Recent corporate developments include upcoming Q3 2026 earnings release on October 21 and successful commercial transformation initiatives driving revenue growth.
LUV presents a compelling value opportunity with attractive valuation metrics (P/S 0.72, EV/EBITDA 8.4) and analyst consensus target of $49.61 offering 19% upside. However, investors face risks from volatile fuel costs, competitive pressures in the airline industry, and inconsistent earnings performance as seen in the Q1 2026 miss. The stock's transformation into a merchandised airline with new revenue streams provides growth catalysts but requires monitoring of execution risks.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
